Abstract: Disclosed is a method of producing lactic acid using a recombinant acid-resistant yeast with inhibited lactate metabolism and alcohol production. More specifically, disclosed are a recombinant acid-resistant yeast in which lactate consumption reaction is reduced and which is imparted with lactic-acid-producing ability to thereby exhibit improved lactic-acid-producing ability and reduced ethanol production, and a method of producing lactic acid using the same.

Abstract: Disclosed are a recombinant acid-resistant yeast having improved lactic-acid-producing ability and a method of preparing lactic acid using the same. When producing lactic acid using the recombinant acid-resistant yeast according to the present invention, not only lactic-acid fermentation can be performed with lactic-acid-producing ability similar to that of bacterial fermentation using a remarkably smaller amount of a neutralizing agent than in the case of conventional bacterial fermentation, but also the production of ethanol and glycerol which are byproducts can be reduced. Thus, fermentation costs can be greatly reduced and the cost of subsequent purification processes can be reduced.

Abstract: Disclosed are a recombinant acid-resistant yeast having lactic acid-producing ability and suppressed glycerol production and a method of preparing lactic acid using the same. More particularly, disclosed are a recombinant acid-resistant yeast into which a gene involved in lactic acid production is introduced and in which a gene involved in glycerol production is deleted or attenuated, and a method of preparing lactic acid using the same. When producing lactic acid using the recombinant acid-resistant yeast, the production of lactic acid is maintained while the production of glycerol is reduced, so crosslinking by glycerol can be suppressed in the oligomerization reaction for conversion to lactide, and thus the conversion yield of lactic acid to lactide can be increased.

Abstract: The present invention relates to an acid-resistant yeast endowed with a lactic acid production ability and having a suppressed ethanol production pathway, and a method for producing lactic acid using same. According to the present invention, by effectively suppressing the production of ethanol in an acid-resistant yeast, and by expressing an LDH enzyme with strong expression and high efficiency, it is possible to produce lactic acid with high yield even at low pH without degrading growth.

Abstract: An image processing apparatus is provided. The image processing apparatus includes a processor configured to, in response to an image including a plurality of frames being input, change a predetermined parameter to a parameter corresponding to a compression rate of each of the plurality of frames for each frame, and process the input image by using the parameter changed for each frame, and an output interface configured to output the processed image.

Abstract: The present invention relates to a novel promoter for regulating ADH gene expression in an organic acid-resistant yeast, and a method of producing an organic acid by expressing an organic acid production-related gene using the same. When an organic acid production-related target gene is expressed in the organic acid-resistant yeast using the novel promoter according to the present invention, there is an advantage in that the yeast can produce the organic acid with high efficiency while having resistance to the organic acid without inhibiting the growth ability of the yeast.

Abstract: An image processing apparatus is provided. The image processing apparatus according to an exemplary embodiment includes a communicator configured to receive an image, and a processor configured to generate a first image obtained by performing image processing on the received image by using a parameter for image processing, generate a second image obtained by reducing the first image at a predetermined ratio, and extract respective visual features from the first image and the second image, wherein the processor is further configured to adjust the parameter to allow a difference between the visual feature of the first image and the visual feature of the second image to be within a predetermined range.

Abstract: The present disclosure relates to a method for preparing an aglycone or hydrolyzed glycoside converted from a glycoside and, specifically, to a method for preparing an aglycone or hydrolyzed glycoside from a glycoside by converting a glycoside into an aglycone form or hydrolyzed glycoside by using a microorganism producing ?-glycosidase, and then recovering the aglycone or hydrolyzed glycoside accumulated in the cells of the microorganism.

Abstract: Provided are a recombinant yeast producing 3-hydroxypropionic acid (3-HP) and a method for producing 3-HP using the same, more particularly, a recombinant yeast producing 3-HP, comprising an exogenous AADH gene; an endogenous or exogenous ACC gene; an exogenous MCR gene; and an exogenous HPDH gene, and producing 3-HP through [Pyruvate Acetaldehyde?Acetyl-CoA Malonyl-CoA Malonate semialdehyde 3-HP] biosynthesis pathway, and a method for producing 3-HP using the same.

Abstract: The present disclosure relates to a method for preparing an aglycone or hydrolyzed glycoside converted from a glycoside and, specifically, to a method for preparing an aglycone or hydrolyzed glycoside from a glycoside by converting a glycoside into an aglycone form or hydrolyzed glycoside by using a microorganism producing ?-glycosidase, and then recovering the aglycone or hydrolyzed glycoside accumulated in the cells of the microorganism.

Abstract: A surveillance system is provided. The surveillance system includes: a first frequency communication module configured to receive a first surveillance image from a first camera, and receive a second surveillance image from a second camera; a second frequency communication module configured to receive second frequency communication module notice information from the second camera; and a processor configured to change a reception signal gain value of the first frequency communication module based on the second frequency communication module notice information, wherein a reception signal strength of the first surveillance image is different from a reception signal strength of the second surveillance image.

Abstract: The present invention relates to a pharmaceutical composition including (i) as a major ingredient, a novel 5-{4-(Aminosulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone compound (Formula 1) or a pharmaceutically acceptable salt thereof, which has a crystalline form A or G, or a mixed form thereof and has a 50% volume particle diameter (d(0.5)) of 3 ?m to 9 ?m and a 90% volume particle diameter (d(0.9)) of 10 ?m to 50 ?m, (ii) a pharmaceutically acceptable diluent, and (iii) a pharmaceutically acceptable lubricant. The pharmaceutical composition of the present invention has the advantages of good stability, high dissolution rate, improved content uniformity, and excellent pharmacokinetic properties. Due to these advantages, as a non-steroidal anti-inflammatory drug, the pharmaceutical composition of the present invention may be effective in treating inflammation or pain.

Abstract: The present invention provides a fed-batch culture method comprising a step of fed-batch-feeding a carbon source base and a base in such a manner that the pH level can be maintained at a level suitable for the growth of microorganisms for fermentation of a carbon source. The present invention also provides a method for preparing organic acids using the fed-batch culture method. The present invention fed-batch-feeds a neutralizing agent such as ammonium bicarbonate, ammonium carbonate or alkali metal-containing weak base, and a carbon source substrate in preparing organic acids by microorganism fermentation. Thus, a pH level suitable for the survival of microorganisms for carbon source fermentation can be maintained, and the speed of injecting the carbon source base which is the source material can be appropriately adjusted.

Abstract: A surveillance system is provided. The surveillance system includes: a first frequency communication module configured to receive a first surveillance image from a first camera, and receive a second surveillance image from a second camera; a second frequency communication module configured to receive second frequency communication module notice information from the second camera; and a processor configured to change a reception signal gain value of the first frequency communication module based on the second frequency communication module notice information, wherein a reception signal strength of the first surveillance image is different from a reception signal strength of the second surveillance image.

Abstract: An image processing apparatus is provided. The image processing apparatus includes a processor configured to, in response to an image including a plurality of frames being input, change a predetermined parameter to a parameter corresponding to a compression rate of each of the plurality of frames for each frame, and process the input image by using the parameter changed for each frame, and an output interface configured to output the processed image.

Abstract: An image processing apparatus is provided. The image processing apparatus according to an exemplary embodiment includes a communicator configured to receive an image, and a processor configured to generate a first image obtained by performing image processing on the received image by using a parameter for image processing, generate a second image obtained by reducing the first image at a predetermined ratio, and extract respective visual features from the first image and the second image, wherein the processor is further configured to adjust the parameter to allow a difference between the visual feature of the first image and the visual feature of the second image to be within a predetermined range.

Abstract: The present invention relates to a pharmaceutical composition including (i) as a major ingredient, a novel 5-{4-(Aminosulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone compound (Formula 1) or a pharmaceutically acceptable salt thereof, which has a crystalline form A or G, or a mixed form thereof and has a 50% volume particle diameter (d(0.5)) of 3 ?m to 9 ?m and a 90% volume particle diameter (d(0.9)) of 10 ?m to 50 ?m, (ii) a pharmaceutically acceptable diluent, and (iii) a pharmaceutically acceptable lubricant. The pharmaceutical composition of the present invention has the advantages of good stability, high dissolution rate, improved content uniformity, and excellent pharmacokinetic properties. Due to these advantages, as a non-steroidal anti-inflammatory drug, the pharmaceutical composition of the present invention may be effective in treating inflammation or pain.

Abstract: The present disclosure relates to a method for preparing an aglycone or hydrolyzed glycoside converted from a glycoside and, specifically, to a method for preparing an aglycone or hydrolyzed glycoside from a glycoside by converting a glycoside into an aglycone form or hydrolyzed glycoside by using a microorganism producing ?-glycosidase, and then recovering the aglycone or hydrolyzed glycoside accumulated in the cells of the microorganism.

Abstract: Provided are a recombinant yeast producing 3-hydroxypropionic acid (3-HP) and a method for producing 3-HP using the same, more particularly, a recombinant yeast producing 3-HP, comprising an exogenous AADH gene; an endogenous or exogenous ACC gene; an exogenous MCR gene; and an exogenous HPDH gene, and producing 3-HP through [Pyruvate Acetaldehyde?Acetyl-CoA Malonyl-CoA Malonate semialdehyde 3-HP] biosynthesis pathway, and a method for producing 3-HP using the same.

Abstract: Provided herein is a mutant microorganism containing a methylmalonyl-CoA reductase-encoding gene having an activity of converting methylmalonyl-CoA to methylmalonate semialdehyde and uses of the mutant microorganism. The mutant microorganism includes a gene encoding kingdom Archaea-derived methylmalonyl-CoA reductase.